PMID- 27910030
OWN - NLM
STAT- MEDLINE
DCOM- 20180112
LR  - 20180423
IS  - 1940-6029 (Electronic)
IS  - 1064-3745 (Linking)
VI  - 1541
DP  - 2017
TI  - Recurrent Cytogenetic Abnormalities in Non-Hodgkin's Lymphoma and Chronic 
      Lymphocytic Leukemia.
PG  - 279-293
AB  - Characteristic chromosomal translocations are found to be associated with 
      subtypes of B-cell non-Hodgkin lymphoma (NHL), for example t(8;14)(q24;q32) and 
      Burkitt lymphoma, t(14;18)(q32;q21) and follicular lymphoma, and 
      t(11;14)(q13;q32) in mantle cell lymphoma. Only few recurrent cytogenetic 
      aberrations have been identified in the T-cell NHL and the best known is the ALK 
      gene translocation t(2;5)(p23;q35) in anaplastic large cell lymphoma. Since lymph 
      node or other tissue is seldom submitted for conventional cytogenetics study, 
      alternative approaches for translocation detection are polymerase chain reaction 
      (PCR) or fluorescence in situ hybridization (FISH). FISH is more sensitive than 
      PCR in the detection of lymphoma translocations since directly labeled large FISH 
      probes that span the translocation breakpoints are used. Although the recurrent 
      chromosomal abnormalities in NHL are not completely sensitive and specific for 
      disease entities, unlike the scenario in acute leukemia, cytogenetic and 
      molecular genetic study is commonly used to aid lymphoma diagnosis and 
      classification. Currently, the main clinical utility is in the employment of 
      interphase FISH panels to predict disease aggressiveness to guide therapy, for 
      example identification of double-hit lymphoma, or in prognostication, for example 
      risk-stratification in chronic lymphocytic leukemia. The recent application of 
      high-throughput sequencing to NHL not only advances the understanding of disease 
      pathogenesis and classification, but allows the discovery of new drug targets, 
      such as BRAF gene inhibition in hairy cell leukemia. Coupled with the increasing 
      availability of novel molecular targeted therapeutic agents, the hope for the 
      future is to translate the genetics and genomics information to achieve 
      personalized medicine in NHL.
FAU - Ma, Edmond S K
AU  - Ma ES
AD  - Department of Pathology, Hong Kong Sanatorium & Hospital, 2 Village Road, Happy 
      Valley, Hong Kong. eskma@hksh.com.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Methods Mol Biol
JT  - Methods in molecular biology (Clifton, N.J.)
JID - 9214969
RN  - 0 (Oncogene Proteins, Fusion)
SB  - IM
MH  - *Chromosome Aberrations
MH  - Genetic Association Studies
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*diagnosis/drug 
      therapy/*genetics/mortality
MH  - Lymphoma, Non-Hodgkin/*diagnosis/*genetics
MH  - Molecular Targeted Therapy
MH  - Oncogene Proteins, Fusion/genetics
MH  - Prognosis
MH  - Translocation, Genetic
OTO - NOTNLM
OT  - Chromosomal translocation
OT  - Classification
OT  - Cytogenetics
OT  - Diagnosis
OT  - FISH
OT  - Molecular targeted therapy
OT  - Non-Hodgkin lymphoma
OT  - PCR
OT  - Personalized medicine
OT  - Prognosis
EDAT- 2016/12/03 06:00
MHDA- 2018/01/13 06:00
CRDT- 2016/12/03 06:00
PHST- 2016/12/03 06:00 [entrez]
PHST- 2016/12/03 06:00 [pubmed]
PHST- 2018/01/13 06:00 [medline]
AID - 10.1007/978-1-4939-6703-2_22 [doi]
PST - ppublish
SO  - Methods Mol Biol. 2017;1541:279-293. doi: 10.1007/978-1-4939-6703-2_22.